<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01649830</url>
  </required_header>
  <id_info>
    <org_study_id>2012012</org_study_id>
    <nct_id>NCT01649830</nct_id>
  </id_info>
  <brief_title>Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma</brief_title>
  <official_title>Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low-grade glioma (LGG) is a common primary brain tumor in young adults. The infiltrative
      nature and frequent growth in eloquent area in brain often makes total resection impossible.
      Until now, no agreement has been achieved on the treatment of LGG without total resection.
      Post-radiation adjuvant temozolomide (TMZ) is currently the standard of care for high-grade
      gliomas. Radiotherapy or TMZ is recommended for the treatment of residue low-grade gliomas.
      However, the efficacy of combined radiotherapy with adjuvant TMZ for residue LGG remains to
      be defined. In this randomized controlled trial, the investigators will test the hypothesis
      that radiotherapy with subsequent TMZ chemotherapy is superior to improve the
      progression-free survival of patients with residue LGG without significant impairment to
      quality of life compared to radiotherapy alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Astrocytoma</condition>
  <condition>Oligodendroglioma</condition>
  <condition>Oligodendroastrocytoma</condition>
  <arm_group>
    <arm_group_label>Radiotherapy plus adjuvant temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks. Four weeks after radiotherapy, patients will then receive 6 cycle of temozolomide dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation therapy will start within 8 weeks after neurosurgical procedures. The residue gliomas will receive a total dose of 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.</description>
    <arm_group_label>Radiotherapy plus adjuvant temozolomide</arm_group_label>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.</description>
    <arm_group_label>Radiotherapy plus adjuvant temozolomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 years to 60 years

          -  Incompletely resected supratentorial WHO II astrocytoma, oligodendroglioma or
             oligodendroastrocytoma

          -  Karnofsky Performance Score â‰¥ 60

          -  Adequate bone marrow, liver and renal function

          -  Ability of subject to understand character and individual consequences of the clinical
             trial

          -  Written informed consent

        Exclusion Criteria:

          -  Refusal to participate the study

          -  Known hypersensitivity or contraindication to temozolomide

          -  Previous irradiation, prior radiosurgery or prior chemotherapy

          -  Pregnant or lactating females

          -  Malignant tumor other than brain tumor

          -  Contraindicated for MRI examination

          -  Unable to comply with the follow-up studies of this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-ping CHEN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong-ping CHEN, MD, PhD</last_name>
    <phone>+86-20-87343310</phone>
    <email>chenzhp@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ke SAI, MD, PhD</last_name>
    <phone>+86-20-87343656</phone>
    <email>saike@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Zhong-ping CHEN, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 20, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2012</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhongping Chen</investigator_full_name>
    <investigator_title>Professor and Chair, Department of Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>low-grade glioma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

